CA2805511C - Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique - Google Patents

Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique Download PDF

Info

Publication number
CA2805511C
CA2805511C CA2805511A CA2805511A CA2805511C CA 2805511 C CA2805511 C CA 2805511C CA 2805511 A CA2805511 A CA 2805511A CA 2805511 A CA2805511 A CA 2805511A CA 2805511 C CA2805511 C CA 2805511C
Authority
CA
Canada
Prior art keywords
riboflavin
concentration
treatment
solution
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2805511A
Other languages
English (en)
French (fr)
Other versions
CA2805511A1 (en
Inventor
Salvatore Troisi
Antonio Del Prete
Ciro Caruso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000052A external-priority patent/ITVA20090052A1/it
Priority claimed from IT000044A external-priority patent/ITVA20100044A1/it
Application filed by Individual filed Critical Individual
Publication of CA2805511A1 publication Critical patent/CA2805511A1/en
Application granted granted Critical
Publication of CA2805511C publication Critical patent/CA2805511C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2805511A 2009-07-27 2010-07-23 Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique Active CA2805511C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITVA2009A000052 2009-07-27
IT000052A ITVA20090052A1 (it) 2009-07-27 2009-07-27 Composizione per il trattamento del cheratocono con tecnica di cross-linking trans-epiteliale o per proteggere strutture interne del globo oculare da raggi uv-a
ITVA2010A000044 2010-05-20
IT000044A ITVA20100044A1 (it) 2010-05-20 2010-05-20 Soluzione oftalmica per proteggere strutture interne del globo oculare da raggi uv-a o per il trattamento del cheratocono con tecnica di cross-linking trans-epiteliale
PCT/EP2010/060752 WO2011012557A1 (en) 2009-07-27 2010-07-23 Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique

Publications (2)

Publication Number Publication Date
CA2805511A1 CA2805511A1 (en) 2011-02-03
CA2805511C true CA2805511C (en) 2017-04-11

Family

ID=42575807

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2805511A Active CA2805511C (en) 2009-07-27 2010-07-23 Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique

Country Status (13)

Country Link
US (1) US9192594B2 (enExample)
EP (1) EP2459186B1 (enExample)
JP (1) JP2013500302A (enExample)
KR (1) KR20120038520A (enExample)
CN (1) CN102470120A (enExample)
AU (1) AU2010277668A1 (enExample)
BR (1) BR112012001998B8 (enExample)
CA (1) CA2805511C (enExample)
ES (1) ES2441227T3 (enExample)
PT (1) PT2459186E (enExample)
RU (1) RU2540481C2 (enExample)
WO (1) WO2011012557A1 (enExample)
ZA (1) ZA201201122B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US8668727B2 (en) 2011-08-23 2014-03-11 Anthony Natale Systems and methods for treating pathogenic infection
US9023092B2 (en) 2011-08-23 2015-05-05 Anthony Natale Endoscopes enhanced with pathogenic treatment
CN102429767B (zh) * 2011-08-25 2016-03-09 广东福地新视野光电技术有限公司 激光角膜热成形术系统
ITMI20120355A1 (it) * 2012-03-07 2013-09-08 Ciro Caruso Sostanza colorante per uso diagnostico oftalmologico
EP2830554A1 (en) 2012-03-29 2015-02-04 CXL Ophthalmics, LLC Ocular cross-linking system and method for sealing corneal wounds
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
ITRM20130248A1 (it) * 2013-04-24 2014-10-25 Medivis S R L Formulazioni di riboflavina per il cross-linking transepiteliale.
RU2683651C2 (ru) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
RU2556791C1 (ru) * 2014-06-09 2015-07-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения кератоконуса
WO2017015471A1 (en) * 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
WO2018156593A1 (en) * 2017-02-21 2018-08-30 Avedro, Inc. Formulations for eye treatments
IT201900011985A1 (it) * 2019-07-17 2021-01-17 Vision Eng Italy Srl Formulazione liquida, in particolare per trattare un tessuto corneale
IT201900021849A1 (it) 2019-11-21 2021-05-21 Bf Res S R L Lente a contatto morbida e confezione comprendente tale lente a contatto
JP2026120924A (ja) * 2023-04-28 2026-07-23 株式会社 メドレックス 眼科用組成物
CN118845755B (zh) * 2024-08-27 2025-08-15 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 大豆异黄酮在制备用于治疗圆锥角膜药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106669A (zh) 1994-10-10 1995-08-16 华中理工大学 一种防治白内障的滴眼液
US5780446A (en) 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
ITMI981586A1 (it) * 1998-07-10 2000-01-10 Giorgio Panin Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose
US6291519B1 (en) * 1998-10-14 2001-09-18 Novartis Ag Method of preventing damage to eye tissue
IT1307281B1 (it) * 1999-11-25 2001-10-30 Simonelli Giuseppe Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
RU2201213C1 (ru) * 2001-07-04 2003-03-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Глазные капли "карнозин"
JP5147156B2 (ja) * 2003-08-08 2013-02-20 ロート製薬株式会社 角膜障害抑制剤
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
JP4604515B2 (ja) 2004-03-05 2011-01-05 大正製薬株式会社 眼科用剤
ITMI20052036A1 (it) * 2005-10-26 2007-04-27 Professional Dietetics Srl Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
ITRM20070356A1 (it) * 2007-06-26 2008-12-27 Sooft Italia Srl Soluzione oculare sterile monouso e suo procedimento di produzione per il cross linking corneale del cheratocono

Also Published As

Publication number Publication date
BR112012001998B8 (pt) 2021-05-25
BR112012001998A2 (pt) 2017-01-31
CN102470120A (zh) 2012-05-23
WO2011012557A1 (en) 2011-02-03
BR112012001998B1 (pt) 2020-12-01
US20120121567A1 (en) 2012-05-17
EP2459186A1 (en) 2012-06-06
PT2459186E (pt) 2013-12-24
ES2441227T3 (es) 2014-02-03
JP2013500302A (ja) 2013-01-07
KR20120038520A (ko) 2012-04-23
US9192594B2 (en) 2015-11-24
CA2805511A1 (en) 2011-02-03
RU2540481C2 (ru) 2015-02-10
AU2010277668A1 (en) 2012-03-01
RU2012106178A (ru) 2013-09-10
EP2459186B1 (en) 2013-10-09
AU2010277668A8 (en) 2012-04-19
ZA201201122B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
EP2459186B1 (en) Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique
Abdelkader et al. Age-related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens
AU2009286285B2 (en) Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders
CN1753683B (zh) 预防和治疗不良眼部病症的眼用制剂
Zhang et al. A review of collagen cross‐linking in cornea and sclera
JP2009501726A (ja) 眼科学的活性剤の製剤とその投与の方法
MX2015005089A (es) Soluciones midriaticas y antiinflamatorias inyectables, estables y libres de conservantes.
EA013931B1 (ru) Способ лечения глазных расстройств
Brookshire et al. Efficacy of COX‐2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal
ES2728071T3 (es) Composiciones oftalmológicas y su uso
EP2647373A1 (en) Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine.
WO1998013038A1 (fr) Inhibiteur de turbidite sous-epitheliale
EP4262809A1 (en) Mydriatic compositions and methods for fabricating thereof
ITVA20100044A1 (it) Soluzione oftalmica per proteggere strutture interne del globo oculare da raggi uv-a o per il trattamento del cheratocono con tecnica di cross-linking trans-epiteliale
Ong-Tone et al. Pupil size with and without adrenaline with diclofenac use before cataract surgery
CA2731871C (en) Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders
Huynh Factors governing photodynamic cross-linking of ocular coat
Huang et al. Therapeutic strategy for corneal edema: Nicotinamide-based anterior chamber perfusion agent for efficacy-verified treatment
RU2440159C1 (ru) Способ торможения процессов пролиферации в сетчатке при ее повреждении
Lim et al. 4 Advances in Corneal Crosslinking
ITVA20090052A1 (it) Composizione per il trattamento del cheratocono con tecnica di cross-linking trans-epiteliale o per proteggere strutture interne del globo oculare da raggi uv-a
Hafezi Cross-linking of corneal collagen with UVA and riboflavin for the treatment of corneal disease
WO2014064697A1 (en) Method of treatment of disease
Walker The effect of Xylocaine Hydrodissection on posterior capsule opacification after cataract surgery
Salah Eldine Corneal Collagen Crosslinking with Riboflavin and Ultraviolet-A Irradiation in the Management of Progressive Ectatic Corneal Disorders. Review Article

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150723

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - SMALL

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240719

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240725

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - SMALL

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250716

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250718

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - SMALL

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260713

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260713